Spiesschaert Bart, Angerer Katharina, Park John, Wollmann Guido
Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University Innsbruck, 6020 Innsbruck, Austria.
Institute of Virology, Medical University Innsbruck, 6020 Innsbruck, Austria.
Cancers (Basel). 2021 Jul 6;13(14):3386. doi: 10.3390/cancers13143386.
The focus of treating cancer with oncolytic viruses (OVs) has increasingly shifted towards achieving efficacy through the induction and augmentation of an antitumor immune response. However, innate antiviral responses can limit the activity of many OVs within the tumor and several immunosuppressive factors can hamper any subsequent antitumor immune responses. In recent decades, numerous small molecule compounds that either inhibit the immunosuppressive features of tumor cells or antagonize antiviral immunity have been developed and tested for. Here we comprehensively review small molecule compounds that can achieve therapeutic synergy with OVs. We also elaborate on the mechanisms by which these treatments elicit anti-tumor effects as monotherapies and how these complement OV treatment.
溶瘤病毒（OVs）治疗癌症的重点已越来越多地转向通过诱导和增强抗肿瘤免疫反应来实现疗效。然而，先天性抗病毒反应会限制许多OVs在肿瘤内的活性，并且一些免疫抑制因子会阻碍随后的任何抗肿瘤免疫反应。近几十年来，已经开发并测试了许多小分子化合物，这些化合物要么抑制肿瘤细胞的免疫抑制特性，要么对抗抗病毒免疫。在此，我们全面综述了能够与OVs实现治疗协同作用的小分子化合物。我们还详细阐述了这些治疗作为单一疗法引发抗肿瘤效应的机制，以及它们如何补充OV治疗。
